GARDNER, Mass.--(BUSINESS WIRE)--New England Peptide (NEP) and the Atlantic Cancer Research Institute (ACRI) announced today that they have jointly submitted a patent application for cancer-related peptide reagents which have the potential to deliver breakthroughs in cancer diagnostics and more individualized therapies for cancer patients.
